Comprehensive Overview of Clinical Staging for Breast Cancer
Introduction to Clinical Staging in Breast Cancer
Instructor Profile: The lecture is delivered by James French, a specialist general surgeon at the Westminster Breast Cancer Institute who practices exclusively in breast surgery.
Definition of Clinical Staging: Staging is a systematic method used to describe the extent of a patient's cancer at the time of their initial presentation.
Evolution of Staging: Since 2018, the staging program has expanded to include five key components, moving beyond simple anatomical measurements to include biological factors.
The Five Key Components of Clinical Staging
Tumour Size ():
Measurement of the primary tumour.
Data is gathered through clinical assessment (physical examination) and imaging assessments.
Imaging modalities used include mammograms, ultrasound, and occasionally Magnetic Resonance Imaging (MRI).
Nodal Disease ():
Refers to the extent of cancer involvement in the lymph nodes.
Recent versions of staging programs have made nodal classification more complex, though clinically, the first one or two classifications are the most frequently utilized.
Metastases ():
Assessment of whether the cancer has spread to distant organs at the time of initial presentation.
This is determined via clinical suspicion or specific staging investigations such as Computed Tomography (CT) examinations and bone scans.
Histological Grade ():
A measure of the aggressiveness of the tumour cells as seen under a microscope.
This component aligns with the "Triple Assessment" workup in breast cancer.
Receptor Status:
The assessment of specific proteins on the cancer cells that guide treatment choice.
The three main receptors evaluated are:
HER2 Receptor: Overexpression is a critical factor for targeted treatment decisions.
Oestrogen Receptors (ER): Degree of expression is measured.
Progesterone Receptors (PR): Degree of expression is measured.
The Clinical Significance of Staging
Prognostic Stratification: Staging allows clinicians to group patients into different prognostic outcome groups, providing vital information for both the patient and the medical team regarding the expected course of the disease.
Communication: It provides a standardized language to help communicate the significance and severity of the cancer to the patient.
Treatment Guidance: Staging is a fundamental tool for determining the most appropriate treatment pathways (e.g., surgery, chemotherapy, hormone therapy).
Research and Comparison: It assists in clinical research by allowing researchers to compare one treatment group to another in clinical trials using standardized patient profiles.
The Triple Assessment and Diagnostic Tools
The Triple Assessment Framework:
History and physical examination.
Imaging findings (Mammogram, Ultrasound, MRI).
Non-surgical biopsy.
Biopsy Standards: Current practice favors Core Needle Biopsy over fine-needle aspiration because it provides a more accurate reflection of the tumour grade and allows for definitive receptor status testing.
Calculation Tools: Because the modern TNM system is complex, clinicians often use the AJCC (American Joint Committee on Cancer) calculator apps, which are available for both Android and Apple devices.
Detailed Breakdown of TNM Classifications
Tumour Size ()
T1: Tumours that are less than in diameter.
Note: More than of patients today are diagnosed through screening programs, and a significant number present with T1 tumours.
T2: Tumours between and () at presentation.
T3: Tumours greater than () at presentation.
T4: Tumours of any size that exhibit specific local complications:
Extension into the underlying chest wall (muscles or rib cage).
Extension into the overlying skin, resulting in ulceration.
T4d (Inflammatory Breast Cancer): Represents approximately of initial presentations. It is defined by more than of the breast surface area being covered in erythema (redness) associated with skin oedema or peau d'orange (skin appearing like an orange peel).
Nodal Status ()
N0: No clinically palpable nodes and no lymph nodes visible on axillary ultrasound.
N1: Presence of mobile ipsilateral nodes (on the same side as the cancer) palpable in the lower axilla.
Advanced N Stages: Includes patients presenting with fixed or matted lymph nodes or involvement of other regional node areas.
Metastatic Status ()
M0: Clinically or radiologically non-metastatic; there is no evidence of disease spread outside of the breast and the axilla.
M1: Evidence of metastatic disease.
Investigations are triggered by palpable axillary nodes, large tumours, or symptoms suggesting systemic spread.
Standard staging investigations include: CT scan of the head, chest, abdomen, and pelvis, combined with a whole-body bone scan.
Positron Emission Tomography (PET) or PET-CT scans may be substituted in some circumstances.
Histological Grading and Pathology
Pathological Parameters: Pathologists evaluate three specific microscopic features to assign a score:
Mitotic Rate: How quickly the cells are dividing.
Nuclear Atypia: How abnormal the cell nuclei appear.
Tubule Formation: The degree to which the cells form structures resembling normal breast tissue.
Scoring: The scores from these parameters are summated to grade the tumour:
Grade 1: Least aggressive.
Grade 3: Most aggressive.
Molecular Platforms: Some international centers use Oncotype DX scorings (a molecular platform), but this is not commonly available or funded in Australia.
Case Studies and Clinical Scenarios
Scenario A: T-Stage Calculation
Patient: 46-year-old female.
Finding: cancer identified on ultrasound.
Classification: This is a T2 tumour (since it falls between and ).
Scenario B: Complex Presentation (Inflammatory/Metastatic)
Patient: 28-year-old female with left breast pain and redness.
Initial Misdiagnosis: Treated as mastitis by her GP with antibiotics, resulting in only partial resolution.
Physical Exam: A mass in the upper outer quadrant with two mobile, firm, non-tender lymph nodes in the lower axilla.
Biopsy Results: Grade 3 invasive carcinoma; ER negative, PR negative, and HER2 negative (Triple Negative Breast Cancer).
Imaging Findings: Liver CT showed a metastasis, and a chest CT showed multiple lung metastases.
Staging Summary:
T-score: T4d (due to inflammatory changes and size).
Nodes: cN1 (mobile palpable axillary nodes).
Metastasis: M1 (liver and lung involvement).
Anatomical Stage: Stage 4.
Prognostic Group: Stage 4.
Clinical Implications: While the cancer may be incurable, it is treatable. The patient will not respond to anti-oestrogen or HER2-targeted therapies. Chemotherapy is the mainstay, and the patient may be eligible for clinical trials.
Summary of Clinical Staging Importance
Staging provides both the patient and clinician with necessary prognostic information.
The combination of tumour biology (grade/receptors) and anatomical staging (TNM) guides the initial treatment plan.
It creates a standardized reporting framework ensuring patients are placed into appropriate clinical trials.
It is fundamentally based on the TNM classification system.